Liposomal Bupivacaine for Acute Pain Management Following Posterior Lumbar Decompression and Fusion Surgery in Adults: A Prospective, Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Spine surgery often causes severe postoperative pain. Currently, our hospital routinely uses ropivacaine for local infiltration analgesia (lasting 6-8 hours). This study evaluates liposomal bupivacaine, a novel long-acting local anesthetic providing up to 72 hours of pain relief, in patients undergoing posterior lumbar spine surgery. Through a randomized controlled design, we will compare the two drugs' effects on pain control within 72 hours and opioid consumption. Both regimens are guideline-recommended and safe.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years;

• ASA physical status class I-III;

• Scheduled for elective 1- or 2-level posterior lumbar surgery: Decompression (laminectomy/discectomy) and fusion with internal fixation

Locations
Other Locations
China
Peking University Third Hospital
RECRUITING
Beijing
Contact Information
Primary
Min Li
liminanesth@bjmu.edu.cn
+8613522757239
Backup
Wenwen Zhai
zhaiwenwen_1987@163.com
+8613811523204
Time Frame
Start Date: 2025-09-20
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 204
Treatments
Experimental: Liposomal Bupivacaine Group
266 mg liposomal bupivacaine + 25 mg bupivacaine HCl, local infiltration during closure
Active_comparator: Ropivacaine Group
120 mg ropivacaine, local infiltration during closure.
Related Therapeutic Areas
Sponsors
Leads: Min Li

This content was sourced from clinicaltrials.gov